Therapeutic Potential of a Polymer-Encapsulated l-DOPA and Dopamine-Producing Cell Line in Rodent and Primate Models of Parkinson’s Disease
Identifieur interne : 002096 ( Main/Corpus ); précédent : 002095; suivant : 002097Therapeutic Potential of a Polymer-Encapsulated l-DOPA and Dopamine-Producing Cell Line in Rodent and Primate Models of Parkinson’s Disease
Auteurs : Mark D. Lindner ; Dwaine F. EmerichSource :
- Cell Transplantation [ 0963-6897 ] ; 1998.
English descriptors
- KwdEn :
Abstract
Encapsulation of cells within polymer membranes prior to transplantation provides a novel means of achieving continuous, site-specific delivery of therapeutic molecules to the CNS. The use of encapsulated dopamine-secreting cells that can be transplanted directly into the striatum has particular appeal for the treatment of Parkinson’s disease. This article provides a brief and timely review of the progress that has been made over the past decade using encapsulated PC12 cells as a means of delivering dopamine and l-DOPA to the striatum in rodent and primate models of Parkinson’s disease. The polymer membranes are well tolerated and biocompatible. Encapsulated PC12 cells survive in vivo for up to 6 mo, they release dopamine into the surrounding host striatum, and they clearly improve behavioral function in both dopamine-depleted rodents and primates. Although these results are promising, fundamental issues remain concerning the extent of dopamine diffusion from the polymer membranes and the number of devices needed for behavioral improvement, and the duration and consistency of cell viability and device output. Nevertheless, this technology appears to be a promising means of avoiding many of the practical, societal, and ethical issues that have been associated with other transplantation approaches.
Url:
DOI: 10.1016/S0963-6897(97)00169-3
Links to Exploration step
ISTEX:A632BE0E80A18D147C1960D1A41E82480ABEB39CLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Therapeutic Potential of a Polymer-Encapsulated l-DOPA and Dopamine-Producing Cell Line in Rodent and Primate Models of Parkinson’s Disease</title><author><name sortKey="Lindner, Mark D" sort="Lindner, Mark D" uniqKey="Lindner M" first="Mark D" last="Lindner">Mark D. Lindner</name><affiliation><mods:affiliation>CytoTherapeutics Inc., Lincoln, RI 02865, USA</mods:affiliation></affiliation></author><author><name sortKey="Emerich, Dwaine F" sort="Emerich, Dwaine F" uniqKey="Emerich D" first="Dwaine F" last="Emerich">Dwaine F. Emerich</name><affiliation><mods:affiliation>Alkermes Inc., Cambridge, MA 02139, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A632BE0E80A18D147C1960D1A41E82480ABEB39C</idno><date when="1998" year="1998">1998</date><idno type="doi">10.1016/S0963-6897(97)00169-3</idno><idno type="url">https://api.istex.fr/document/A632BE0E80A18D147C1960D1A41E82480ABEB39C/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002096</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Therapeutic Potential of a Polymer-Encapsulated l-DOPA and Dopamine-Producing Cell Line in Rodent and Primate Models of Parkinson’s Disease</title><author><name sortKey="Lindner, Mark D" sort="Lindner, Mark D" uniqKey="Lindner M" first="Mark D" last="Lindner">Mark D. Lindner</name><affiliation><mods:affiliation>CytoTherapeutics Inc., Lincoln, RI 02865, USA</mods:affiliation></affiliation></author><author><name sortKey="Emerich, Dwaine F" sort="Emerich, Dwaine F" uniqKey="Emerich D" first="Dwaine F" last="Emerich">Dwaine F. Emerich</name><affiliation><mods:affiliation>Alkermes Inc., Cambridge, MA 02139, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Cell Transplantation</title><title level="j" type="abbrev">CTR</title><idno type="ISSN">0963-6897</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1998">1998</date><biblScope unit="volume">7</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="165">165</biblScope><biblScope unit="page" to="174">174</biblScope></imprint><idno type="ISSN">0963-6897</idno></series><idno type="istex">A632BE0E80A18D147C1960D1A41E82480ABEB39C</idno><idno type="DOI">10.1016/S0963-6897(97)00169-3</idno><idno type="PII">S0963-6897(97)00169-3</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0963-6897</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal models</term><term>Cell line</term><term>Encapsulation technology</term><term>Parkinson’s disease</term><term>Potential efficacy</term><term>Transplantation</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Encapsulation of cells within polymer membranes prior to transplantation provides a novel means of achieving continuous, site-specific delivery of therapeutic molecules to the CNS. The use of encapsulated dopamine-secreting cells that can be transplanted directly into the striatum has particular appeal for the treatment of Parkinson’s disease. This article provides a brief and timely review of the progress that has been made over the past decade using encapsulated PC12 cells as a means of delivering dopamine and l-DOPA to the striatum in rodent and primate models of Parkinson’s disease. The polymer membranes are well tolerated and biocompatible. Encapsulated PC12 cells survive in vivo for up to 6 mo, they release dopamine into the surrounding host striatum, and they clearly improve behavioral function in both dopamine-depleted rodents and primates. Although these results are promising, fundamental issues remain concerning the extent of dopamine diffusion from the polymer membranes and the number of devices needed for behavioral improvement, and the duration and consistency of cell viability and device output. Nevertheless, this technology appears to be a promising means of avoiding many of the practical, societal, and ethical issues that have been associated with other transplantation approaches.</div></front></TEI><istex><corpusName>elsevier</corpusName><author><json:item><name>Mark D Lindner</name><affiliations><json:string>CytoTherapeutics Inc., Lincoln, RI 02865, USA</json:string></affiliations></json:item><json:item><name>Dwaine F Emerich</name><affiliations><json:string>Alkermes Inc., Cambridge, MA 02139, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Encapsulation technology</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson’s disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Animal models</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Cell line</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Transplantation</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Potential efficacy</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Encapsulation of cells within polymer membranes prior to transplantation provides a novel means of achieving continuous, site-specific delivery of therapeutic molecules to the CNS. The use of encapsulated dopamine-secreting cells that can be transplanted directly into the striatum has particular appeal for the treatment of Parkinson’s disease. This article provides a brief and timely review of the progress that has been made over the past decade using encapsulated PC12 cells as a means of delivering dopamine and l-DOPA to the striatum in rodent and primate models of Parkinson’s disease. The polymer membranes are well tolerated and biocompatible. Encapsulated PC12 cells survive in vivo for up to 6 mo, they release dopamine into the surrounding host striatum, and they clearly improve behavioral function in both dopamine-depleted rodents and primates. Although these results are promising, fundamental issues remain concerning the extent of dopamine diffusion from the polymer membranes and the number of devices needed for behavioral improvement, and the duration and consistency of cell viability and device output. Nevertheless, this technology appears to be a promising means of avoiding many of the practical, societal, and ethical issues that have been associated with other transplantation approaches.</abstract><qualityIndicators><score>7.316</score><pdfVersion>1.2</pdfVersion><pdfPageSize>596 x 795 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>6</keywordCount><abstractCharCount>1317</abstractCharCount><pdfWordCount>6298</pdfWordCount><pdfCharCount>43551</pdfCharCount><pdfPageCount>10</pdfPageCount><abstractWordCount>193</abstractWordCount></qualityIndicators><title>Therapeutic Potential of a Polymer-Encapsulated l-DOPA and Dopamine-Producing Cell Line in Rodent and Primate Models of Parkinson’s Disease</title><pii><json:string>S0963-6897(97)00169-3</json:string></pii><genre><json:string>research-article</json:string></genre><host><volume>7</volume><pii><json:string>S0963-6897(00)X0022-X</json:string></pii><pages><last>174</last><first>165</first></pages><issn><json:string>0963-6897</json:string></issn><issue>2</issue><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><title>Cell Transplantation</title><publicationDate>1998</publicationDate></host><categories><wos><json:string>MEDICINE, RESEARCH & EXPERIMENTAL</json:string><json:string>TRANSPLANTATION</json:string><json:string>CELL & TISSUE ENGINEERING</json:string><json:string>CELL BIOLOGY</json:string></wos></categories><publicationDate>1998</publicationDate><copyrightDate>1998</copyrightDate><doi><json:string>10.1016/S0963-6897(97)00169-3</json:string></doi><id>A632BE0E80A18D147C1960D1A41E82480ABEB39C</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/A632BE0E80A18D147C1960D1A41E82480ABEB39C/fulltext/pdf</uri></json:item><json:item><original>true</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/A632BE0E80A18D147C1960D1A41E82480ABEB39C/fulltext/txt</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/A632BE0E80A18D147C1960D1A41E82480ABEB39C/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/A632BE0E80A18D147C1960D1A41E82480ABEB39C/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Therapeutic Potential of a Polymer-Encapsulated l-DOPA and Dopamine-Producing Cell Line in Rodent and Primate Models of Parkinson’s Disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>ELSEVIER</publisher><availability><p>ELSEVIER</p></availability><date>1998</date></publicationStmt><notesStmt><note type="content">Section title: Original Contributions</note><note type="content">Fig. 1: Apomorphine-induced rotations in rats with severe unilateral dopamine depletions. The number of contralateral rotations was the same for all groups before implanting devices. After device implantations, the number of apomorphine-induced rotations was substantially reduced, but only in rats with polymer-encapsulated PC12 cells implanted in the striatum, and only as long as the devices remained implanted [28]. These results also suggest that the therapeutic effect is not a nonspecific effect related to invasive surgical procedures in the denervated striatum. If that were the case, rats with devices removed from the striatum would continue to exhibit a reduction in apomorphine-induced rotations.</note><note type="content">Fig. 2: Composite Parkinsonian score produced by combining four behavioral measures of parkinsonian symptoms. Both oral Sinemet and encapsulated PC12-cell devices attenuated the degree of parkinsonism in the affected forelimb on measures of akinesia, rigidity, and sensorimotor neglect. Asterisks mark all points at which performance with the affected limb was significantly improved relative to the Control group with vehicle only.</note><note type="content">Fig. 3: Variability in device performance after explantation. Combined dopamine and l-DOPA output from rodent-sized devices after approximately 4 mo in vivo [48].</note><note type="content">Fig. 4: Variability in device performance after explantation from MPTP primates. Each line represents combined dopamine and l-DOPA output in each of five devices implanted in each monkey after more than 6 mo in vivo [43]. These results suggest that there are individual differences between hosts that affect device performance. Note that all the devices explanted from one MPTP monkey (open circles) had virtually 0 output, while output from all five devices in another MPTP monkey had very high output (open squares) and all five devices from another MPTP monkey were in the intermediate range. Preimplant device catecholamine output was equivalent in all three monkeys.</note><note type="content">Table 1: Behavioral Effects of Encapsulated PC12 Cells in Animal Models of Parkinson’s Disease</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Therapeutic Potential of a Polymer-Encapsulated l-DOPA and Dopamine-Producing Cell Line in Rodent and Primate Models of Parkinson’s Disease</title><author><persName><forename type="first">Mark D</forename><surname>Lindner</surname></persName><note type="biography">Mark D. Lindner, Ph.D., CytoTherapeutics, Inc., 701 George Washington Highway, Lincoln, RI 02865.</note><affiliation>Mark D. Lindner, Ph.D., CytoTherapeutics, Inc., 701 George Washington Highway, Lincoln, RI 02865.</affiliation><affiliation>CytoTherapeutics Inc., Lincoln, RI 02865, USA</affiliation></author><author><persName><forename type="first">Dwaine F</forename><surname>Emerich</surname></persName><affiliation>Alkermes Inc., Cambridge, MA 02139, USA</affiliation></author></analytic><monogr><title level="j">Cell Transplantation</title><title level="j" type="abbrev">CTR</title><idno type="pISSN">0963-6897</idno><idno type="PII">S0963-6897(00)X0022-X</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1998"></date><biblScope unit="volume">7</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="165">165</biblScope><biblScope unit="page" to="174">174</biblScope></imprint></monogr><idno type="istex">A632BE0E80A18D147C1960D1A41E82480ABEB39C</idno><idno type="DOI">10.1016/S0963-6897(97)00169-3</idno><idno type="PII">S0963-6897(97)00169-3</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1998</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Encapsulation of cells within polymer membranes prior to transplantation provides a novel means of achieving continuous, site-specific delivery of therapeutic molecules to the CNS. The use of encapsulated dopamine-secreting cells that can be transplanted directly into the striatum has particular appeal for the treatment of Parkinson’s disease. This article provides a brief and timely review of the progress that has been made over the past decade using encapsulated PC12 cells as a means of delivering dopamine and l-DOPA to the striatum in rodent and primate models of Parkinson’s disease. The polymer membranes are well tolerated and biocompatible. Encapsulated PC12 cells survive in vivo for up to 6 mo, they release dopamine into the surrounding host striatum, and they clearly improve behavioral function in both dopamine-depleted rodents and primates. Although these results are promising, fundamental issues remain concerning the extent of dopamine diffusion from the polymer membranes and the number of devices needed for behavioral improvement, and the duration and consistency of cell viability and device output. Nevertheless, this technology appears to be a promising means of avoiding many of the practical, societal, and ethical issues that have been associated with other transplantation approaches.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Encapsulation technology</term></item><item><term>Parkinson’s disease</term></item><item><term>Animal models</term></item><item><term>Cell line</term></item><item><term>Transplantation</term></item><item><term>Potential efficacy</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1998">Published</change></revisionDesc></teiHeader></istex:fulltextTEI></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: ce:floats; body; tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"><istex:entity SYSTEM="gr1" NDATA="IMAGE" name="gr1"></istex:entity><istex:entity SYSTEM="gr2" NDATA="IMAGE" name="gr2"></istex:entity><istex:entity SYSTEM="gr3" NDATA="IMAGE" name="gr3"></istex:entity><istex:entity SYSTEM="gr4" NDATA="IMAGE" name="gr4"></istex:entity></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla" xml:lang="en"><item-info><jid>CTR</jid><aid>5132</aid><ce:pii>S0963-6897(97)00169-3</ce:pii><ce:doi>10.1016/S0963-6897(97)00169-3</ce:doi><ce:copyright year="1998" type="full-transfer">Elsevier Science Inc.</ce:copyright></item-info><head><ce:dochead><ce:textfn>Original Contributions</ce:textfn></ce:dochead><ce:title>Therapeutic Potential of a Polymer-Encapsulated <ce:small-caps>l</ce:small-caps>-DOPA and Dopamine-Producing Cell Line in Rodent and Primate Models of Parkinson’s Disease</ce:title><ce:author-group><ce:author><ce:indexed-name>Lindner</ce:indexed-name><ce:given-name>Mark D</ce:given-name><ce:surname>Lindner</ce:surname><ce:cross-ref refid="AFF1">A</ce:cross-ref><ce:cross-ref refid="CORR1">*</ce:cross-ref></ce:author><ce:author><ce:indexed-name>Emerich</ce:indexed-name><ce:given-name>Dwaine F</ce:given-name><ce:surname>Emerich</ce:surname><ce:cross-ref refid="AFF2">B</ce:cross-ref></ce:author><ce:affiliation id="AFF1"><ce:label>A</ce:label><ce:textfn>CytoTherapeutics Inc., Lincoln, RI 02865, USA</ce:textfn></ce:affiliation><ce:affiliation id="AFF2"><ce:label>B</ce:label><ce:textfn>Alkermes Inc., Cambridge, MA 02139, USA</ce:textfn></ce:affiliation><ce:correspondence id="CORR1"><ce:label>*</ce:label><ce:text>Mark D. Lindner, Ph.D., CytoTherapeutics, Inc., 701 George Washington Highway, Lincoln, RI 02865.</ce:text></ce:correspondence></ce:author-group><ce:abstract><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para>Encapsulation of cells within polymer membranes prior to transplantation provides a novel means of achieving continuous, site-specific delivery of therapeutic molecules to the CNS. The use of encapsulated dopamine-secreting cells that can be transplanted directly into the striatum has particular appeal for the treatment of Parkinson’s disease. This article provides a brief and timely review of the progress that has been made over the past decade using encapsulated PC12 cells as a means of delivering dopamine and <ce:small-caps>l</ce:small-caps>-DOPA to the striatum in rodent and primate models of Parkinson’s disease. The polymer membranes are well tolerated and biocompatible. Encapsulated PC12 cells survive in vivo for up to 6 mo, they release dopamine into the surrounding host striatum, and they clearly improve behavioral function in both dopamine-depleted rodents and primates. Although these results are promising, fundamental issues remain concerning the extent of dopamine diffusion from the polymer membranes and the number of devices needed for behavioral improvement, and the duration and consistency of cell viability and device output. Nevertheless, this technology appears to be a promising means of avoiding many of the practical, societal, and ethical issues that have been associated with other transplantation approaches.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords><ce:section-title>Keywords</ce:section-title><ce:keyword><ce:text>Encapsulation technology</ce:text></ce:keyword><ce:keyword><ce:text>Parkinson’s disease</ce:text></ce:keyword><ce:keyword><ce:text>Animal models</ce:text></ce:keyword><ce:keyword><ce:text>Cell line</ce:text></ce:keyword><ce:keyword><ce:text>Transplantation</ce:text></ce:keyword><ce:keyword><ce:text>Potential efficacy</ce:text></ce:keyword></ce:keywords></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Therapeutic Potential of a Polymer-Encapsulated l-DOPA and Dopamine-Producing Cell Line in Rodent and Primate Models of Parkinson’s Disease</title></titleInfo><titleInfo type="alternative" lang="en" contentType="CDATA"><title>Therapeutic Potential of a Polymer-Encapsulated</title></titleInfo><name type="personal"><namePart type="given">Mark D</namePart><namePart type="family">Lindner</namePart><affiliation>CytoTherapeutics Inc., Lincoln, RI 02865, USA</affiliation><description>Mark D. Lindner, Ph.D., CytoTherapeutics, Inc., 701 George Washington Highway, Lincoln, RI 02865.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Dwaine F</namePart><namePart type="family">Emerich</namePart><affiliation>Alkermes Inc., Cambridge, MA 02139, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article"></genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1998</dateIssued><copyrightDate encoding="w3cdtf">1998</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">Encapsulation of cells within polymer membranes prior to transplantation provides a novel means of achieving continuous, site-specific delivery of therapeutic molecules to the CNS. The use of encapsulated dopamine-secreting cells that can be transplanted directly into the striatum has particular appeal for the treatment of Parkinson’s disease. This article provides a brief and timely review of the progress that has been made over the past decade using encapsulated PC12 cells as a means of delivering dopamine and l-DOPA to the striatum in rodent and primate models of Parkinson’s disease. The polymer membranes are well tolerated and biocompatible. Encapsulated PC12 cells survive in vivo for up to 6 mo, they release dopamine into the surrounding host striatum, and they clearly improve behavioral function in both dopamine-depleted rodents and primates. Although these results are promising, fundamental issues remain concerning the extent of dopamine diffusion from the polymer membranes and the number of devices needed for behavioral improvement, and the duration and consistency of cell viability and device output. Nevertheless, this technology appears to be a promising means of avoiding many of the practical, societal, and ethical issues that have been associated with other transplantation approaches.</abstract><note type="content">Section title: Original Contributions</note><note type="content">Fig. 1: Apomorphine-induced rotations in rats with severe unilateral dopamine depletions. The number of contralateral rotations was the same for all groups before implanting devices. After device implantations, the number of apomorphine-induced rotations was substantially reduced, but only in rats with polymer-encapsulated PC12 cells implanted in the striatum, and only as long as the devices remained implanted [28]. These results also suggest that the therapeutic effect is not a nonspecific effect related to invasive surgical procedures in the denervated striatum. If that were the case, rats with devices removed from the striatum would continue to exhibit a reduction in apomorphine-induced rotations.</note><note type="content">Fig. 2: Composite Parkinsonian score produced by combining four behavioral measures of parkinsonian symptoms. Both oral Sinemet and encapsulated PC12-cell devices attenuated the degree of parkinsonism in the affected forelimb on measures of akinesia, rigidity, and sensorimotor neglect. Asterisks mark all points at which performance with the affected limb was significantly improved relative to the Control group with vehicle only.</note><note type="content">Fig. 3: Variability in device performance after explantation. Combined dopamine and l-DOPA output from rodent-sized devices after approximately 4 mo in vivo [48].</note><note type="content">Fig. 4: Variability in device performance after explantation from MPTP primates. Each line represents combined dopamine and l-DOPA output in each of five devices implanted in each monkey after more than 6 mo in vivo [43]. These results suggest that there are individual differences between hosts that affect device performance. Note that all the devices explanted from one MPTP monkey (open circles) had virtually 0 output, while output from all five devices in another MPTP monkey had very high output (open squares) and all five devices from another MPTP monkey were in the intermediate range. Preimplant device catecholamine output was equivalent in all three monkeys.</note><note type="content">Table 1: Behavioral Effects of Encapsulated PC12 Cells in Animal Models of Parkinson’s Disease</note><subject lang="en"><genre>Keywords</genre><topic>Encapsulation technology</topic><topic>Parkinson’s disease</topic><topic>Animal models</topic><topic>Cell line</topic><topic>Transplantation</topic><topic>Potential efficacy</topic></subject><relatedItem type="host"><titleInfo><title>Cell Transplantation</title></titleInfo><titleInfo type="abbreviated"><title>CTR</title></titleInfo><genre type="Journal">journal</genre><originInfo><dateIssued encoding="w3cdtf">199803</dateIssued></originInfo><identifier type="ISSN">0963-6897</identifier><identifier type="PII">S0963-6897(00)X0022-X</identifier><part><date>199803</date><detail type="volume"><number>7</number><caption>vol.</caption></detail><detail type="issue"><number>2</number><caption>no.</caption></detail><extent unit="issue pages"><start>83</start><end>226</end></extent><extent unit="pages"><start>165</start><end>174</end></extent></part></relatedItem><identifier type="istex">A632BE0E80A18D147C1960D1A41E82480ABEB39C</identifier><identifier type="DOI">10.1016/S0963-6897(97)00169-3</identifier><identifier type="PII">S0963-6897(97)00169-3</identifier><accessCondition type="use and reproduction" contentType="">© 1998Elsevier Science Inc.</accessCondition><recordInfo><recordContentSource>ELSEVIER</recordContentSource><recordOrigin>Elsevier Science Inc., ©1998</recordOrigin></recordInfo></mods></metadata><enrichments><istex:catWosTEI uri="https://api.istex.fr/document/A632BE0E80A18D147C1960D1A41E82480ABEB39C/enrichments/catWos"><teiHeader><profileDesc><textClass><classCode scheme="WOS">MEDICINE, RESEARCH & EXPERIMENTAL</classCode><classCode scheme="WOS">TRANSPLANTATION</classCode><classCode scheme="WOS">CELL & TISSUE ENGINEERING</classCode><classCode scheme="WOS">CELL BIOLOGY</classCode></textClass></profileDesc></teiHeader></istex:catWosTEI></enrichments><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002096 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 002096 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:A632BE0E80A18D147C1960D1A41E82480ABEB39C
|texte= Therapeutic Potential of a Polymer-Encapsulated l-DOPA and Dopamine-Producing Cell Line in Rodent and Primate Models of Parkinson’s Disease
}}
| This area was generated with Dilib version V0.6.23. |  |